Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Slični predmeti

• Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
  od: Piero Barbanti, i dr.
  Izdano: (2022-04-01)
• Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
  od: Piero Barbanti, i dr.
  Izdano: (2023-03-01)
• Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
  od: Piero Barbanti, i dr.
  Izdano: (2024-03-01)
• Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
  od: Root S, i dr.
  Izdano: (2023-02-01)
• Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
  od: Piero Barbanti, i dr.
  Izdano: (2024-08-01)